ArticleRegenerative biomaterials2015
Neuropeptide Y receptors: a promising target for cancer imaging and therapy.
Article in Regenerative biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Stabilized thioamide peptide agonists of the neuropeptide Y type 2 receptor for targeted cancer imaging.RSC chemical biology · 2026Article
- Review
- Neuropeptide Y in cancer-biological functions and potential clinical implications.Cancer metastasis reviews · 2025Review
- Nanomaterial-assisted pancreatic cancer theranostics.Regenerative biomaterials · 2025Review
- Heterobivalent Dual-Target Peptide for Integrin-αPharmaceuticals (Basel, Switzerland) · 2024Article
- The role of central neurotransmitters in appetite regulation of broilers and layers: similarities and differences.Veterinary research communications · 2024Review
- Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.ACS pharmacology & translational science · 2024Review
- Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies.International journal of molecular sciences · 2023Review
- Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling.BMC cancer · 2023Article
- Article
- NPFFR2 Contributes to the Malignancy of Hepatocellular Carcinoma Development by Activating RhoA/YAP Signaling.Cancers · 2022Article
- An Overview of the Molecular Cues and Their Intracellular Signaling Shared by Cancer and the Nervous System: From Neurotransmitters to Synaptic Proteins, Anatomy of an All-Inclusive Cooperation.International journal of molecular sciences · 2022Review
- DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort.Cancer cell international · 2022Article
- Neurotransmitters: Potential Targets in Glioblastoma.Cancers · 2022Review
- Binding of Natural Peptide Ligands to the Neuropeptide YAngewandte Chemie (International ed. in English) · 2022Article
- Review
- Identification of hub genes in gastric cancer by integrated bioinformatics analysis.Translational cancer research · 2021Article
- Sympathetic and parasympathetic innervation in cancer: therapeutic implications.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021Review
- Gene Expression Profile of the Human Colorectal Carcinoma LoVo Cells Treated With Sporamin and Thapsigargin.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropeptide Y (NPY) was first identified from porcine brain in 1982, and plays its biological functions in humans through NPY receptors (Y1, Y2, Y4 and Y5). NPY receptors are known to mediate various physiological functions and involve in a majority of human diseases, such as obesity, hypertension, epilepsy and metabolic disorders. Recently, NPY receptors have been found to be overexpressed in many cancers, so they emerged as promising target in cancer diagnosis and therapy. This review focuses on the latest research about NPY and NPY receptors, and summarizes the current knowledge on NPY receptors expression in cancers, selective ligands for NPY receptors and their application in cancer imaging and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.